证券代码：688246 证券简称：嘉和美康 公告编号：2024-049 嘉和美康（北京）科技股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本次业绩说明会以网络互动形式召开，公司将针对 2024 年第三季度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点及方式 （一）会议召开时间：2024 年 11 月 28 日下午 14:00-15:00 会议召开时间：2024 年 11 月 28 日（星期四）下午 14:00-15:00 会 议 召 开 地 点 ： 上海证券 交易所上证路演中心（ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 （二）会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心网络互动 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担 ...

Investment Rating - The report assigns a rating of "Accumulate" for the company, indicating a positive outlook for the stock over the next six months [4]. Core Insights - The company has maintained its leadership in the electronic medical record (EMR) market in China for ten consecutive years, with over 1,700 hospital clients, including more than 650 top-tier hospitals [2]. - The company is enhancing its AI capabilities, launching centralized decision support engines and an open platform for medical AI applications, which have been successfully implemented in major hospitals [2]. - The company is focusing on promoting integrated data management to help hospitals develop the value of their data assets, with successful implementations already in place [3]. - The financial performance for Q3 2024 showed a revenue decline of 28.68% year-on-year, with a net loss of 0.14 billion yuan, reflecting ongoing challenges [1]. - The company expects a recovery in profitability from 2024 to 2026, with projected net profits of 0.81 billion yuan, 1.27 billion yuan, and 1.86 billion yuan respectively, leading to a price-to-earnings ratio (PE) of 52, 33, and 23 times [3]. Financial Summary - For the first three quarters of 2024, the company reported revenues of 476 million yuan, a decrease of 11.52% year-on-year, and a net loss of 41 million yuan, a significant decline of 328.81% [1]. - The company’s total assets were reported at 2,646.90 million yuan for 2023, with a total market capitalization of 4,237.18 million yuan [4][7]. - The company’s operating income for 2024 is projected to be 778.60 million yuan, with a growth rate of 12% [7][11].

Investment Rating - The investment rating for the company is "Buy," indicating an expected return exceeding 10% relative to the CSI 300 index over the next six months [3][13]. Core Insights - The company has maintained its leading position in the electronic medical record (EMR) industry, achieving the highest market share from 2013 to 2023. It has over 1,700 hospital clients, including 650 tier-3 hospitals, representing more than 25% of all tier-3 hospitals in the country [8][9]. - The company reported a revenue of 476 million yuan for the first three quarters of 2024, a year-on-year decrease of 11.52%. The net profit attributable to shareholders was -41 million yuan, compared to a profit of 18 million yuan in the same period last year [3]. - The company has a strong focus on product innovation, with 30 core technologies in various medical fields, including clinical applications and big data utilization [3][8]. Financial Summary - For Q3 2024, the company achieved a revenue of 175 million yuan, down 28.68% year-on-year, with a net profit of -14 million yuan, compared to a profit of 41 million yuan in the same quarter last year [3]. - The gross margin for the first three quarters of 2024 was 47.29%, a decrease of 2.48 percentage points year-on-year. The company’s operating expenses remained stable, but the expense ratio increased due to declining revenues [3][9]. - The projected diluted EPS for 2024, 2025, and 2026 are 0.53 yuan, 0.84 yuan, and 1.13 yuan, respectively, with corresponding dynamic P/E ratios of 57.27, 36.25, and 26.92 [9][11]. Market Position and Future Outlook - The company is expected to benefit from the ongoing standardization of public data and information in the healthcare sector, which will likely increase demand for smart healthcare solutions [8][9]. - The company’s products have high market recognition, and with the continuous growth in healthcare information needs, its performance is anticipated to improve significantly in the future [9].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook despite short-term challenges [8]. Core Insights - The company reported a revenue of 476 million yuan for the first three quarters of 2024, a decrease of 11.52% year-on-year, and a net profit attributable to shareholders of -41 million yuan, compared to 18 million yuan in the same period last year [5][6]. - The third quarter of 2024 saw a revenue of 175 million yuan, down 28.68% year-on-year, and a net profit of -14 million yuan, which was below previous expectations [6]. - The company has maintained its leading position in the electronic medical record (EMR) market for ten consecutive years, leveraging AI to enhance its growth potential [7]. - The company is focusing on cost control while increasing R&D investment, leading to a slight decline in gross margin but improved cash flow [6][7]. Financial Data Summary - The total revenue for 2023 was 695 million yuan, with projections of 800 million yuan for 2024, 961 million yuan for 2025, and 1,153 million yuan for 2026 [9][11]. - The net profit for 2024 is projected to be 88 million yuan, with significant growth expected in subsequent years [9][11]. - The gross margin for 2024 is expected to be 52.0%, with a return on equity (ROE) projected at 4.6% [9].

国泰君安版权所有发送给上海东方财富金融数据服务有限公司.东财接收研报邮箱.ybjieshou@eastmoney.com p1 股 票 研 究 公 司 更 新 报 告 证 券 研 究 报 告 股票研究 /[Table_Date] 2024.10.31 ——嘉和美康 2024 年三季报点评 Q3 业绩仍承压，利用新兴技术持续强化产品竞争力 嘉和美康(688246) 计算机 [Table_Industry] /信息科技 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------|-------|-------|-------------------|-------|--------|-------|-------|-------|-----------------------------| | | | | | | | | | | | | [table_Authors] | | | 李博伦 ( 分析师 ) | | 陈剑鑫 | | | | ( 研究助理 ) | | | | | 0755-23976516 | | | ...

证券代码：688246 证券简称：嘉和美康 公告编号：2024-048 单位：人民币元 项目 2024 年 1-9 月计提金额 原因 信用减值损失 26,357,140.33 参考历史信用损失经验， 结合当前状况及未来经 济状况的预测，按照未来 12 个月或整个存续期预 期信用损失，编制账龄与 预期信用损失率对照表， 以此为基础计算预期信 用损失。 资产减值损失 7,697,910.80 参考历史信用损失经验， 结合当前状况及未来经 | | | 济状况的预测，按照整个 | | --- | --- | --- | | | | 存续期预期信用损失，编 | | | | 制账龄与预期信用损失 | | | | 率对照表，以此为基础计 | | | | 算合同资产预期信用损 | | | | 失；对存货资产，在资产 | | | | 负债表日，存货成本高于 | | | | 其可变现净值的，计提存 | | | | 货跌价准备。 | | 合计 | 34,055,051.13 | / | 二、计提减值准备事项的具体说明 （一）信用减值损失 公司以预期信用损失为基础，对应收票据、应收账款、其他应收款进行了减 值测试。经测试，本次需计提 ...

证券代码：688246 证券简称：嘉和美康 公告编号：2024-047 嘉和美康（北京）科技股份有限公司 关于 2022 年股票期权与限制性股票激励计划 2024 年第三季度自主行权结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 ●本次行权数量： 嘉和美康（北京）科技股份有限公司（以下简称"公司"）2022 年股票期权与 限制性股票激励计划首次授予的股票期权第一个行权期可行权数量为 42.2236 万 份，行权期为 2023 年 9 月 15 日至 2024 年 7 月 14 日。2024 年 7 月 1 日至 2024 年 7 月 14 日期间，累计行权并完成股份过户登记数量为 788 股，占本次可行权 总量的 0.19%；截至 2024 年 7 月 14 日，累计行权数量与完成股份过户登记数量 为 152,144 股，占本次可行权总量的 36.03%。 嘉和美康（北京）科技股份有限公司 2022 年股票期权与限制性股票激励计 划预留授予的股票期权第一个行权期可行权数量为 5.2130 ...

华泰联合证券有限责任公司 关于嘉和美康（北京）科技股份有限公司 2024 年半年度持续督导跟踪报告 | 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司简称：嘉和美康 | | --- | --- | | 保荐代表人姓名：孔祥熙 | 联系电话：010-56839300 | | 保荐代表人姓名：王琛 | 联系电话：010-56839300 | 根据《中华人民共和国证券法》《证券发行上市保荐业务管理办法》和《上 海证券交易所科创板股票上市规则》等有关法律、法规的规定，华泰联合证券有 限责任公司（以下简称"华泰联合证券"或"保荐机构"）作为嘉和美康（北京） 科技股份有限公司（以下简称"嘉和美康"、"公司"）首次公开发行股票的保荐 机构，对嘉和美康进行持续督导，并出具 2024 年半年度（以下简称"报告期"） 持续督导跟踪报告： 一、保荐机构和保荐代表人发现的问题及整改情况 2024 年 1-6 月，公司实现营业收入 30,047.76 万元，较上年同期增长 2.92%； 实现归属于上市公司股东的净利润-2,747.22 万元，归属于上市公司股东的扣除 非经常性损益的净利润-3,073.89 万元，归母净利润、归 ...

收入稳定增长，医疗大模型应用加速落地 嘉和美康（688246）/计算机 证券研究报告/公司点评 2024 年 8 月 28 日 | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------- ...

上 市 公 司 证 券 研 究 报 告 计算机 公 司 研 究/ 公 司 点 评 | --- | --- | |-----------------------------|-------------------------------| | 市场数据： | 2024 年 08 月 20 日 | | 收盘价（元） | 17.19 | | 一年内最高/最低（元） | 37.30/17.02 | | 市净率 | 1.3 | | 息率（分红 / 股价） | | | 流通 A 股市值（百万元） | 1,735 | | 上证指数/深证成指 | 2,866.66/8,252.87 | | --- | --- | |-------------------------------|-------------------------------| | | | | | | | 基础数据 : | 2024 年 06 月 30 日 | | 每股净资产（元） | 13.00 | | | | | 资产负债率 % | 32.97 | | 总股本/流通 A 股（百万） | 138/101 | | 流通 B 股 /H 股（百万） | -/- | ...